Hoxton Planning & Management’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$211K Sell
1,308
-196
-13% -$32.7K 0.05% 218
2026
Q2
$285K Buy
1,504
+40
+3% +$7.52K 0.07% 184
2026
Q1
$289K Sell
1,464
-50
-3% -$9.6K 0.09% 167
2025
Q4
$278K Buy
1,514
+49
+3% +$8.59K 0.08% 169
2025
Q3
$225K Buy
+1,465
New +$222K 0.07% 194
2024
Q4
– Sell
-1,331
Closed -$207K – 209
2024
Q3
$207K Hold
1,331
– – 0.08% 195
2024
Q2
$208K Buy
+1,331
New +$200K 0.1% 152

Other funds holding AZN

Hoxton Planning & Management's AZN Position: Q3 2026 in Review

Hoxton Planning & Management reduced its AstraZeneca (AZN) stake by 13% in Q3 2026, selling an estimated $32.7K and leaving 1,308 shares worth $211K. The position accounts for 0.05% of the portfolio, ranked #218.

Hoxton Planning & Management first reported a position in AZN in Q2 2024 and has held it in 7 quarters since. The position peaked at $289K in Q1 2026. 1,446 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • Hoxton Planning & Management held 1,308 shares of AstraZeneca worth $211K as of Q3 2026.
  • Hoxton Planning & Management sold 196 AstraZeneca shares in Q3 2026, an estimated $32.7K.
  • AstraZeneca made up 0.05% of Hoxton Planning & Management's portfolio in Q3 2026, its #218 holding.
  • Hoxton Planning & Management first reported a position in AstraZeneca in Q2 2024 and has held it in 7 quarters since.
  • Hoxton Planning & Management's AstraZeneca position peaked at $289K in Q1 2026.
  • 1,446 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Hoxton Planning & Management's 13F filing for Q3 2026, filed 15 Oct 2026.